Back to Journals » Drug Design, Development and Therapy » Volume 14

Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects

Authors Shin D, Kim Y, Go A, Velinova M

Received 22 July 2019

Accepted for publication 5 December 2019

Published 8 January 2020 Volume 2020:14 Pages 43—50

DOI https://doi.org/10.2147/DDDT.S224103

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Yan Zhu


Donghoon Shin,1 Younsoo Kim,1 Ahra Go,1 Maria Velinova2

1Samsung Bioepis Co., Ltd., Incheon, Republic of Korea; 2PRA International, Groningen, the Netherlands

Correspondence: Donghoon Shin
Samsung Bioepis Co., Ltd, 107, Cheomdan-daero, Yeonsu-gu, Incheon 21987, Republic of Korea
Tel +82-31-8061-4534
Fax +82-31-8061-4393
Email dh01.shin@samsung.com

Purpose: SB4 is an etanercept biosimilar, approved by the European Commission (EC) and the US Food and Drug Administration (FDA) following a demonstration of equivalent efficacy and safety and comparable quality data to the reference product. This study aimed to demonstrate equivalent pharmacokinetic (PK) profiles, safety, and tolerability between SB4 autoinjector (AI) and SB4 pre-filled syringe (PFS).
Patients and methods: This was an open-label, two-period, two-sequence, single-dose, cross-over study to evaluate bioequivalence of PK profiles, safety, and tolerability between SB4 AI and PFS in healthy adults. Treatment periods were separated by 14 days resulting in a 35-day washout between investigational product (IP) administration in Periods 1 and 2.
Results: A total of 50 subjects were randomized: 24 subjects in Sequence I and 26 in Sequence II, and 6 subjects discontinued from the study. The primary PK endpoints including area under the concentration–time curve from time zero to infinity (AUCinf) and to the last quantifiable concentration (AUClast), and maximum serum concentration (Cmax) were all within the equivalence margin of 80.00–125.00%. Safety and tolerability were comparable between the two treatments.
Conclusion: PK profiles showed that SB4 AI and PFS were bioequivalent in healthy subjects. Safety assessment was also comparable between the two treatments.

Keywords: biosimilar, etanercept, bioequivalence, autoinjector, pre-filled syringe

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]